In theUS, the National Comprehensive Cancer Network (NCCN) recommends PSAtesting every 6 to 12 months for 5 years after PCa treatment, followedby yearly monitoring.33 After radical prostatectomyfor PCa, 3–26% of patients experience biochemical recurrence(BCR), which is defined as PSA values persistently > 0.2 ng/mL.42−,201 Overall, this confirms the high demand for PSA testing for screening,early diagnosis, and recurrence of PCa, which will continue to increasedue to an aging population. The gene discussed is KLK3; the disease is posterior cortical atrophy.